Pfizer Bets $10.5bn On China Cancer Drug With Innovent

Pfizer has committed up to $10.5 billion to license a dozen early-stage cancer drugs from China’s Innovent Biologics, one of the largest oncology deals to emerge from the accelerating global scramble for Chinese biomedical innovation. The agreement, disclosed Wednesday in a Hong Kong stock exchange filing, pairs Pfizer’s global development machinery with Innovent’s pipeline of […]Original Article